JPRN-UMIN000009924
Completed
未知
A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiography - A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiography
Showa University Northern Hospital0 sites100 target enrollmentFebruary 1, 2013
ConditionsHeart Failure
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Heart Failure
- Sponsor
- Showa University Northern Hospital
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)history of allergy against this drug or similar compounds (2\)anuria (urine volume \<100ml/day) (3\)subjects who cannot feel thirsty or have difficulty to drink (4\)subjects whose serum sodium level is over 147mEq/L (5\)subjects who are pregnant or possibly pregnant (6\)subjects who already have tolvaptan at the entry (7\)acute coronary syndrome (8\)patients who are judged to be inappropriate to this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study to evaluate the dose-response efficacy of body fat reduction by continuous ingestion of test food. (SWE-2023-07-HCRINK)ot applicableJPRN-UMIN000051748Suntory Wellness Limited200
Active, not recruiting
Not Applicable
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-ESaboratorios Dr. Esteve, SA450
Active, not recruiting
Phase 1
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-CZaboratorios Dr. Esteve, SA450
Completed
Phase 2
The Study of Dose Response Relationship Evaluation of AryoSeven in Hemophilia PatientsCondition 1: Congenital Hemophilia A with inhibitors. Condition 2: Congenital Hemophilia B with inhibitors.Hereditary factor VIII deficiencyHereditary factor IX deficiencyIRCT20161202031193N3AryoGen Pharmed12
Terminated
Phase 2
To identify the effective dose(s) of RT234 (vardenafil inhalation powder) to acutely improve pulmonary vascular haemodynamics in study participants with Pulmonary Arterial Hypertension (PAH).Pulmonary Arterial HypertensionCardiovascular - Other cardiovascular diseasesACTRN12619001178134Respira Therapeutics Australia Pty Ltd14